CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and ...

"Publication of the new AMA CPT code represents a significant milestone for Sensydia, and will help foster the adoption of our nninvasive, in-clinic hemodynamic assessment tool by establishing a ...

AliveCor, the global leader in AI-powered cardiology, today announced it has received U.S. Food and Drug Administration (FDA) ...

The newly cleared features include three rhythm modifiers and two axis-related morphology determinations: RAD and LAD.

Elucid today announced that, effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I ...

Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5%Full year revenue expected to be $56.5 ...

The latest announcement is out from CVRx ( (CVRX) ).

Cleerly, a leader in AI-based cardiovascular imaging, today announced that Aetna will begin covering Cleerly® LABS plaque analysis effective immediately. Aetna, which covers more than 20+ million ...

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

On 15 January 2026, President Donald J. Trump released "The Great Healthcare Plan" from the White House-a comprehensive ...

AngioDynamics shows how product mix shifts toward higher-margin Med Tech platforms are quietly reshaping earnings power ...